肝病患者血小板输注情况调查分析  

Analysis of Platelet Transfusion in Liver Disease Patient

作　　者：王淑英[1] 周文辉[2] 李新颖[3] 张扬丽[1] 牛国涛[1] 冯艳青[1] 

机构地区：[1]中国人民解放军302医院输血科,北京100039 [2]北京中国人民解放军302医院医务部,100039 [3]北京中国人民解放军302医院生物治疗科,100039

出　　处：《临床输血与检验》2017年第4期328-331,共4页Journal of Clinical Transfusion and Laboratory Medicine

摘　　要：目的调查肝病专科医院患者血小板临床应用的现状,为进一步分析血小板在肝病患者的临床输注研究提供基础。方法收集某医院2015年1~3月机采血小板输注的所有肝病患者的临床和输血资料,对血小板的输注原因、输注剂量、方式及效果等进行统计分析。结果该院输注血小板的疾病多数为乙肝肝硬化和肝癌,主要输注原因为预防性输注(86.5%),其中介入术前改善凝血功能占30.75%;治疗输注仅占20.31%。输注阈值多为(10~40)×10~9/L,血小板的输注效果与肝硬化分级无关,介入术前预防性输注剂量增加,术后血小板计数增加,但出血率无明显下降。结论血小板输注存在不合理现象,急需进一步研究肝病患者预防性输注血小板的阈值和剂量。Objective To provide a basis for further study on platelet transfusion in patients with liver diseases. The status of platelet application was investigated in the liver special hospital. Methods Clinical and platelets transfusion data were collected for all patients who were transfused with aphaeresis platelet from Jan to Mar,2015.The indications,dosage,and effect of platelet transfusion were statistically analyzed. Results The primary diseases in platelets transfusion were liver cirrhosis and liver cancer in the hospital. Prophylactic transfusion was the main reason for platelets use,which accounted for 86.5 percent. 30.75% of platelets transfusion were performed for improving blood coagulation before intervention.Unexpectedly,infusions for treatment only accounted for 20.31%. The threshold of platelet transfusion mostly was （10~40）×109/L. The effect of platelet transfusion was not associated with cirrhosis progress. Conclusion It＇s suggested that the indication and dosage of prophylactic platelets transfusion should be optimized in the patients with hepatic diseases.

关 键 词：预防性血小板输注 治疗性血小板输注 疗效 肝病 

分 类 号：R457.1[医药卫生—治疗学]